Stockscreener 앱 받기
5.63
2.93%
0.16
Nervgen Pharma Corp 주식(NGEN)의 최신 뉴스
NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment - MSN
NervGen Pharma Begins Trading on Nasdaq Today - Sahm
Is NervGen Pharma Corp. (9UA) stock good for wealth creationJuly 2025 Movers & Weekly High Conviction Trade Ideas - Улправда
NervGen Pharma Debuts On Nasdaq - Nasdaq
NervGen Pharma to Begin Trading on Nasdaq - marketscreener.com
NervGen Pharma Lists on Nasdaq to Support Late-Stage Push for Spinal Cord Injury Drug - TipRanks
NervGen Pharma Gets Approval for Listing on Nasdaq - marketscreener.com
NervGen Pharma Brief: Begins Trading on Nasdaq Today - marketscreener.com
This Company’s Drug May Help Regenerate Injured Spinal Cords - Forbes
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS - Yahoo Finance
NervGen Pharma Proposes Amendment to Warrant Terms - TipRanks
This Canadian biotech stock is looking to treat spinal cord injuries - Cantech Letter
NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment - TipRanks
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development - TipRanks
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development - Yahoo Finance
Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth? - Yahoo Finance
Pennsylvania man says experimental drug has helped him recover from cycling accident - CBS News
Nervgen Pharma’s NVG-291 Study: A Potential Breakthrough in Spinal Cord Injury Treatment - TipRanks
NervGen Pharma price target chopped at Research Capital - Cantech Letter
NervGen: A High-Stakes Bet on a Groundbreaking Nerve Repair Drug - NAI500
TSX Penny Stocks To Consider In August 2025 - Yahoo Finance
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury - Yahoo Finance
NervGen Pharma is a buy, Research Capital says - Cantech Letter
NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board - TMX Newsfile
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion - Yahoo Finance
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth - Yahoo Finance
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones - Yahoo Finance
Insights on NervGen Pharma’s Positive Phase 1b/2a Data for NVG-291 in Spinal Cord Injury - NeurologyLive
NervGen Pharma: Risky, Yet Promising With Big Upside - Seeking Alpha
TSX Penny Stocks To Watch In June 2025 - Yahoo Finance
Leaders in health care innovation - BNN Bloomberg
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury - Yahoo Finance
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting - Yahoo Finance
NervGen Pharma Reports Q1 2025 Financial Results and Advances NVG-291 Clinical Development - TipRanks
NGENFNervgen Pharma Corp Latest Stock News & Market Updates - Stock Titan
NervGen Pharma is a high-risk, high-reward stock, analyst says - Cantech Letter
NervGen Initiates Expanded Access Policy - Yahoo Finance
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury - Business Wire
Repairing Spinal Cord Injury Damage - the-scientist.com
Spinal Cord Injury Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail
Undercovered Dozen: OppFi, PowerFleet, Eletrobras, American Battery + - Seeking Alpha
NervGen: Data For Spinal Cord Injury Treatment Candidate Likely For Mid-2025 - Seeking Alpha
NervGen Pharma: Proof that NVG-291 works? | 2024-12-23 | Investing News - Stockhouse
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - TMX Newsfile
Repairing the Spine: Q&A with Mike Kelly, CEO of NervGen - PharmExec.com
NervGen Pharma Appoints Neil Klompas to Board of Directors - TMX Newsfile
NervGen: Are amazing human trial results leaking out? | 2024-07-02 | Investing News - Stockhouse
NervGen Pharma | Biotechnology | The Pharmaletter - The Pharma Letter
Nervgen Pharma advances evaluation of NVG-300 - BioWorld MedTech
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage - Yahoo Finance
Is This Pharma Co. the Next Eli Lilly? - streetwisereports.com
Vancouver biotech NervGen raises $23M in bought deal - Business in Vancouver
Can NervGen keep a lid on explosive news? | 2024-03-20 | Investing News - Stockhouse
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury - Yahoo Finance
Vancouver spinal injury drug gets fast-tracked review - Business in Vancouver
NervGen Pharma Appoints John Ruffolo to Board of Directors - TMX Newsfile
NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates - TMX Newsfile
NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval - Yahoo Finance
NervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury - Yahoo Finance
Advancing Medical Innovations from Battlefield to Mainstream Medicine for Traumatic Brain Injury and Spinal Cord Injury Patients - gritdaily.com
NervGen Completes Dosing Another Group With MS Candidate NVG-291 - Multiple Sclerosis News Today
NervGen: Modulating Immune Cells For Spinal Cord Injury, Multiple Sclerosis And Alzheimer's - Seeking Alpha
NervGen Pharma has potential revolutionary drug, says Paradigm - Cantech Letter
NervGen Pharma Announces Leadership Transition - FinancialContent
NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University - FinancialContent
Biotechnology’s Role in Improving Stroke Outcomes - Contract Pharma
Alzheimer’s Breakthrough: A Disruptive Systemic Approach Is Poised To Demonstrate Value - Technology Networks
NervGen Enrolling Final Group in Trial of Potential MS Therapy NVG-291 - Multiple Sclerosis News Today
How restoring brain plasticity is the key to reversing brain damage - NR Times
#AAN2022 — MS Therapy NVG-291 Deemed Safe, Clinical Trial Expected - Multiple Sclerosis News Today
MS Therapy Candidate NVG-291 Cleared to Enroll 2nd Volunteer Group - Multiple Sclerosis News Today
FOR YOUR HEALTH: Helping The Nervous System Heal Itself - The Town Line Newspaper
NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation - FinancialContent
Trial of NVG-291 for MS to Start Ascending Dosing in Healthy Volunteers - Multiple Sclerosis News Today
4.73%
0.92%
자본화:
|
볼륨(24시간):